Moderna is trading at $237.34, up 4.61%, as investors position ahead of the full Phase 3 melanoma-vaccine data presentation scheduled for October 24. - A reported Bank of America price-target increase is adding support. - The biotech backdrop is supportive, with XBI up 2.10%, alongside M&A activity and positive clinical data elsewhere in the sector. - The move reflects renewed oncology optimism, while trial results remain an upcoming catalyst.